Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205752
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bastos Oreiro, Mariana | - |
dc.contributor.author | Gutierrez, Antonio | - |
dc.contributor.author | Iacoboni, Gloria | - |
dc.contributor.author | López Corral, Lucía | - |
dc.contributor.author | Reguera, Juan Luis | - |
dc.contributor.author | Abrisqueta, Pau | - |
dc.contributor.author | Delgado, Javier | - |
dc.contributor.author | Terol, María José | - |
dc.contributor.author | Hernani, Rafael | - |
dc.contributor.author | Martínez, Nuria | - |
dc.contributor.author | Ortíz, Valentín | - |
dc.contributor.author | Bailen, Rebeca | - |
dc.contributor.author | Gomez Centurión, Ignacio | - |
dc.contributor.author | Caballero, Ana | - |
dc.contributor.author | Sanz, Jaime | - |
dc.contributor.author | Guerra Domínguez, Luisa | - |
dc.contributor.author | Luzardo, Hugo | - |
dc.contributor.author | Mussetti, Alberto | - |
dc.contributor.author | Jiménez Ubieto, Ana | - |
dc.contributor.author | Sancho, Juan Manuel | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Pérez, Antonio | - |
dc.contributor.author | Barba, Pere | - |
dc.contributor.author | Kwon, Mi | - |
dc.contributor.author | Martín García Sancho, Alejandro | - |
dc.date.accessioned | 2024-01-16T22:23:18Z | - |
dc.date.available | 2024-01-16T22:23:18Z | - |
dc.date.issued | 2023-12-01 | - |
dc.identifier.issn | 2666-6367 | - |
dc.identifier.uri | http://hdl.handle.net/2445/205752 | - |
dc.description.abstract | In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with particularly poor prognoses. We recently published our real -world data from Spain, focused on this SCHOLAR-1 refractory group, and compared patients who underwent CAR-T therapy with the previous standard of care. In this study, we found that the efficacy of CAR-T therapy in refractory patients, in terms of progression-free survival (PFS) and overall survival (OS), was superior to that of the treatments available in the pre-CAR-T era. The main objective of these new analyses was to analyze treatment efficacy in terms of response rates and survival for patients with ABCL with or without the SCHOLAR-1 criteria. In addition, we ana-lyzed the prognostic impact of each SCHOLAR-1 criterion independently. Our study aimed to assess the prognostic impact of SCHOLAR-1 criteria on ABCL patients treated with CAR-T therapy in Spain. This multicenter, retrospective, observational study. We included all adult patients treated with commercially available CAR-T cell products and diag-nosed with ABCL different from primary mediastinal large B cell lymphoma between February 2019 and July 2022. Patients meeting any SCHOLAR-1 criteria (progressive disease as the best response to any line of therapy, stable dis-ease as the best response to >4 cycles of first-line therapy or >2 cycles of later-line therapy, or relapse at <12 months after autologous stem cell transplantation [auto-SCT]) in the line of treatment before CAR-T therapy (SCHOLAR-1 group) were compared with those not meeting any of these criteria (non-SCHOLAR-1 group). To analyze the prognos-tic impact of individual SCHOLAR-1 criteria, all the patients who met any of the SCHOLAR-1 criteria at any time were included to assess whether these criteria have the same prognostic impact in the CAR-T era. In addition, patients were grouped according to whether they were refractory to the first line of treatment, refractory to the last line of treatment, or relapsed early after auto-SCT. The PFS and OS were calculated from the time of appearance of the SCHOLAR-1 refractoriness criteria. Of 329 patients treated with CAR-T (169 with axi-cel and 160 with tisa-cel), 52 were in the non-SCHOLAR-1 group and 277 were in the SCHOLAR-1 group. We found significantly better outcomes in the non-SCHOLAR-1 patients compared with the SCHOLAR-1 patients (median PFS of 12.2 and 3.3 months, respectively; P = .009). In addition, axi-cel showed better results in terms of efficacy than tisa-cel for both the non SCHOLAR-1 group (hazard ratio [HR] for PFS, 2.7 [95% confidence interval (CI), 1.1 to 6.7; P = .028]; HR for OS, 7.1 [95% CI, 1.5 to 34.6; P = .015]) and SCHOLAR-1 group (HR for PFS, 1.8 [95% CI, 1.3 to 2.5; P < .001]; HR for OS, 1.8 [95% CI, 1.2 to 2.6; P = .002]), but also significantly more toxicity. Finally, separately analyzing the prognostic impact of each SCHOLAR-1 criterion revealed that refractoriness to the last line of treatment was the variable with the most significant impact on survival. In conclusion, SCHOLAR-1 refractoriness criteria notably influence the efficacy of CAR-T therapy. In our experience, axi-cel showed better efficacy than tisa-cel for both SCHOLAR-1 and non-SCHOLAR-1 patients. Refractoriness to the last line of treatment was the variable with the most significant impact on survival in the CAR-T therapy era.(c) 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.jtct.2023.08.026 | - |
dc.relation.ispartof | Transplantation and Cellular Therapy, 2023, vol. 29, num. 12, p. 747 | - |
dc.relation.uri | https://doi.org/10.1016/j.jtct.2023.08.026 | - |
dc.rights | cc by-nc-nd (c) Bastos Oreiro, Mariana et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Cèl·lules B | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | B cells | - |
dc.title | Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-01-09T11:35:00Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37659694 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S2666636723015087-main.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License